HER-3 expression in HER-2-amplified breast carcinoma

Jacek Czopek; Janusz Pawlęga; Kamil Fijorek; Mirosława Püsküllüoğlu; Paweł Różanowski; Krzysztof Okoń

doi:10.5114/wo.2013.38564

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2013
vol. 17

Send email

Copy url:

abstract:

Original paper

HER-3 expression in HER-2-amplified breast carcinoma

Jacek Czopek

,

Janusz Pawlęga

,

Kamil Fijorek

,

Mirosława Püsküllüoğlu

,

Paweł Różanowski

,

Krzysztof Okoń

Contemp Oncol (Pozn) 2013; 17 (5): 446–449

DOI: https://doi.org/10.5114/wo.2013.38564

Online publish date: 2013/11/14

View full text Get citation

PlumX metrics:

Aim of the study: To determine whether the expression of HER-3 influences the survival of HER-2 positive patients with breast cancer (BC).

Material and methods: In the present work, the expression of HER-3 in a group of 35 HER-2 positive patients with BC was studied by performing immunohistochemistry (IHC) in formalin-fixed paraffin embedded tissues.

Results: Higher HER-3 status if estimated by IHC correlated significantly with older age of the patients. HER-3 expression did not correlate with estrogen or progesterone receptor status, pT or pN. There was also no significant difference in disease-free or overall survival (DFS and OS) between groups with different HER-3 expression, although some tendencies were seen as HER-3 expression in over 50% of cells was a factor of worse 5- and 10-year survival.

Conclusions: Further studies should be performed on a larger group of patients to confirm the prognostic role of HER-3 status determined by IHC in BC.

keywords:

HER-3 expression in HER-2-amplified breast carcinoma

Jacek Czopek , Janusz Pawlęga , Kamil Fijorek , Mirosława Püsküllüoğlu , Paweł Różanowski , Krzysztof Okoń

HER-2, HER-3, immunohistochemistry, prognostic factor

Jacek Czopek

,

Janusz Pawlęga

,

Kamil Fijorek

,

Mirosława Püsküllüoğlu

,

Paweł Różanowski

,

Krzysztof Okoń